Human Epidermal Growth Factor Receptor 2 (HER-2) Negative Breast Cancer Market

By Type of Treatment;

Chemotherapy, Radiation, Hormonal Therapy, and Others

By Stage;

Early Stage, Locally Advanced Stage, and Metastatic Stage

By Distribution Channel;

Hosptial and Clinic

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn113441766 Published Date: June, 2025 Updated Date: July, 2025

HER-2 Negative Breast Cancer Market Overview

HER-2 Negative Breast Cancer Market (USD Million)

HER-2 Negative Breast Cancer Market was valued at USD 15,269.41 million in the year 2024. The size of this market is expected to increase to USD 29,926.59 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 10.1%.


Human Epidermal Growth Factor Receptor 2 (HER-2) Negative Breast Cancer Market

*Market size in USD million

CAGR 10.1 %


Study Period2025 - 2031
Base Year2024
CAGR (%)10.1 %
Market Size (2024)USD 15,269.41 Million
Market Size (2031)USD 29,926.59 Million
Market ConcentrationLow
Report Pages382
15,269.41
2024
29,926.59
2031

Major Players

  • AstraZeneca
  • Bristol-Myers Squibb
  • Eli Lilly
  • Pfizer
  • Novartis
  • Pfizer
  • GlaxoSmithKline
  • Novartis
  • Merck
  • Eli Lilly

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Human Epidermal Growth Factor Receptor 2 (HER-2) Negative Breast Cancer Market

Fragmented - Highly competitive market without dominant players


The HER-2 Negative Breast Cancer Market is expanding as cases of breast cancer without HER-2 protein overexpression continue to increase. These cases represent nearly 75% of all diagnosed breast cancers. Enhanced diagnostic capabilities and awareness campaigns have improved early identification, prompting the adoption of targeted treatment pathways for these patients.

Evolving Treatment Frameworks
Advances in treatment have led to significant improvements in care for HER-2 negative patients. About 60% of patients are now responding well to hormone therapies, while newer chemotherapy regimens offer better tolerance and efficacy. Triple-negative breast cancer, a major HER-2 negative subtype, is seeing innovation through immune-chemotherapy combinations.

Rising Role of Immunotherapy
Immunotherapy is gaining prominence in treating HER-2 negative breast cancer. Around 40% of patients with specific genetic markers benefit from immune checkpoint inhibitors. With growing emphasis on PD-L1 testing and tumor-infiltrating lymphocytes, this approach is becoming an integral part of advanced treatment models.

Innovation Fueled by Trials and Alliances
Research intensity in HER-2 negative breast cancer is on the rise. Around 48% of breast cancer clinical trials focus on HER-2 negative indications, reflecting a strong R&D focus. Strategic collaborations between pharmaceutical companies and research institutions are furthering access to next-generation therapies and enhancing clinical success.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Type of Treatment
    2. Market Snapshot, By Stage
    3. Market Snapshot, By Distribution Channel
    4. Market Snapshot, By Region
  4. HER-2 Negative Breast Cancer Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Oncology Innovation
        2. Therapeutic Advancements
        3. Precision Medicine
        4. Multidisciplinary Collaboration
      2. Restraints
        1. Treatment Limitations
        2. Regulatory Hurdles
        3. Economic Constraints
        4. Clinical Challenges
      3. Opportunities
        1. Precision Medicine
        2. Immunotherapy
        3. Targeted Therapies
        4. Personalized Treatment
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. HER-2 Negative Breast Cancer Market, By Type of Treatment, 2021-2031 (USD Million)
      1. Chemotherapy
      2. Radiation
      3. Hormonal Therapy
      4. Others
    2. HER-2 Negative Breast Cancer Market, By Stage, 2021-2031 (USD Million)
      1. Early Stage
      2. Locally Advanced Stage
      3. Metastatic Stage
    3. HER-2 Negative Breast Cancer Market, By Distribution channel, 2021-2031 (USD Million)
      1. Hosptial
      2. Clinic
    4. HER-2 Negative Breast Cancer Market, By Geography, 2021-2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. AstraZeneca
      2. Bristol-Myers Squibb
      3. Eli Lilly
      4. Pfizer
      5. Novartis
      6. Pfizer
      7. GlaxoSmithKline
      8. Novartis
      9. Merck
      10. Eli Lilly
  7. Analyst Views
  8. Future Outlook of the Market